Section 5: Patient Safety and Quality Assurance

5PSQ-028

CARDIOVASCULAR RISK FACTOR IN INDIVIDUALS WITH GENDER IDENTITY DISORDER OR CROSS-SEX HORMONE THERAPY

5PSQ-026

EFFICACY AND SAFETY OF EVOLOCUMAB IN HYPERCHOLESTEROLAEMIA AND MIXED DYSLIPIDAEMIA

5PSQ-025

REAL-WORLD EFFECTIVENESS AND SAFETY OF EVOLOCUMAB AND ALIROCUMAB

5PSQ-011

EVALUATION OF ADHERENCE TO NEW ORAL ANTICOAGULANTS THERAPY BASED ON THERAPEUTIC SWITCHES: A DESCRIPTIVE STUDY

5PSQ-010

EFFICACY AND SAFETY OF AGALSIDASE ALFA IN FABRY DISEASE

5PSQ-006

SAFE MANAGEMENT OF DIABETIC KETOACIDOSIS IN THE EMERGENCY SERVICE

5PSQ-005

BULLOUS PHEMPHIGOID ASSOCIATED WITH GLIPTINS: REVIEW OF LITERATURE AND CASE REPORT

5PSQ-004

ADEQUACY AND EFFECTIVENESS OF LIRAGLUTIDE IN PATIENTS WITH TYPE-2 DIABETES MELLITUS

Pages